The FDA has approved the first rapid hepatitis C virus test for the U.S. market that can be used in patient care settings. The test, which was validated in part by the NIH RADx Tech program with funding from CDC, can provide results in about one hour, meaning patients with a positive test can begin treatment right away. We're honored to have been a part of the journey behind this important milestone! 

Learn more about this game changer for hepatitis C diagnosis >

News and Events

HIV VL Test Annoucement

New Funding Opportunity: Have an innovative solution to detect HIV viral load?

The National Institute of Biomedical Imaging and Bioengineering’s (NIBIB) Point of Care Technology Research Network (POCTRN) is seeking innovative technologies that determine HIV viral load and accelerate their development towards deployment at point-of-care settings

This program is designed to meet the significant unmet need to provide better viral load testing in point-of-care settings with technologies that are both sensitive and simple to use so that people living with HIV can be better informed of their infectiveness and response to antiretroviral therapy.

Awardees will receive:

  • Up to $500k in funding to help support project acceleration
  • Support provided to address business, regulatory, clinical, and technical elements
  • Mentorship from highly experienced experts in all four categories

The deadline for this opportunity has passed.

Questions?  
Please contact admin@poctrn.org.

Our Lasting Impact

As an early pioneer in managing translational research, Cimit has directly supported over 1,200 innovator teams and reviewed or consulted on over 5,000 ideas since our founding in 1998.

We work collaboratively with healthtech innovators, entrepreneurs, and institutions to ultimately make a positive impact on patient care across the globe. We streamline pathways to progress through our efficient processes, established systems, and unparalleled market expertise.